Satoshi Morita

Kyoto, 6068507, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 298 publications

Clinical value of prostate-specific antigen halving time as a predictor of response to first-line systemic treatment for synchronous metastatic castration-sensitive prostate cancer.

Clinical value of prostate-specific antigen halving time as a predictor of response to first-line systemic treatment for synchronous metastatic castration-sensitive prostate cancer.

Journal: International journal of clinical oncology
Published: June 19, 2026

Determining the cutpoint of a continuous predictive biomarker via Bayesian sensitive subpopulation finding.

Determining the cutpoint of a continuous predictive biomarker via Bayesian sensitive subpopulation finding.

Journal: Journal of biopharmaceutical statistics
Published: June 02, 2026

Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10).

Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10).

Journal: BMJ open
Published: May 13, 2026

Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial.

Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial.

Journal: BMJ open
Published: April 21, 2026

Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.

Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.

Journal: Breast cancer (Tokyo, Japan)
Published: March 30, 2026

Development and Validation of Clinical Scoring System to Estimate Mucus Plug Presence in Asthma.

Development and Validation of Clinical Scoring System to Estimate Mucus Plug Presence in Asthma.

Journal: The journal of allergy and clinical immunology. In practice
Published: March 13, 2026

Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study.

Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study.

Journal: ESMO gastrointestinal oncology
Published: February 06, 2026

Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.

Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.

Journal: Breast cancer research and treatment
Published: December 26, 2025

A novel quantitative method for CT assessment of bronchiectasis using AI-based airway segmentation and upper limits of normal airway caliber.

A novel quantitative method for CT assessment of bronchiectasis using AI-based airway segmentation and upper limits of normal airway caliber.

Journal: Respiratory research
Published: December 22, 2025

Associations of sleep duration and nocturnal oxygenation with OCT-derived retinal arterial structure.

Associations of sleep duration and nocturnal oxygenation with OCT-derived retinal arterial structure.

Journal: Microvascular research
Published: December 20, 2025

Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study.

Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study.

Journal: ESMO open
Published: December 19, 2025

Exploring Sensitive Biomarkers Associated With Short-Term Responses and Long-Term Outcomes Using Bayesian Additive Regression Trees.

Exploring Sensitive Biomarkers Associated With Short-Term Responses and Long-Term Outcomes Using Bayesian Additive Regression Trees.

Journal: Statistics in medicine
Published: December 12, 2025
Showing 1-12 of 298

Last Updated: 09/26/2026